Insider Transactions in Q3 2022 at G1 Therapeutics, Inc. (GTHX)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 20
2022
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
20,000
-14.71%
|
$260,000
$13.5 P/Share
|
|
Sep 20
2022
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.82%
|
$0
$0.39 P/Share
|
|
Sep 13
2022
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,000
-19.74%
|
$270,000
$15.71 P/Share
|
|
Sep 13
2022
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+16.48%
|
$0
$0.39 P/Share
|
|
Aug 16
2022
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
80,000
-40.82%
|
$960,000
$12.64 P/Share
|
|
Aug 16
2022
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+28.99%
|
$0
$0.39 P/Share
|
|
Jul 05
2022
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
648
-3.01%
|
$3,240
$5.17 P/Share
|
|
Jul 05
2022
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
648
-0.88%
|
$3,240
$5.17 P/Share
|